Digmbio LOGO

DIGMBIO IN THE NEWS

Digmbio in the News 목록
DigmBio Aims to Initiate Phase 1 Trial of Novel TAS1R3 Agonist for AD Late Next Year This article is available to BioS+ subscribers only.  READ MORE Biospectator July 2, 2026
DigmBio Targets Big Pharma with Next-Gen Brain Metastasis Pipeline . READ MORE MONEYTODAY June 17, 2026
DigmBio and BIK Therapeutics Partner to Co-Develop PARP-1-Targeted Radiopharmaceuticals . READ MORE Hit News June 16, 2026
DigmBio Receives FDA IND Clearance for Phase 2 Trial of DM5167 . READ MORE Hankyung May 19, 2026
DigmBio Selected for Korea’s ‘DIPS 1000+’ . READ MORE Medipana April 13, 2026
19 Korean Biotech Startups Advance to the Global Stage . READ MORE Herald Corporation April 6, 2026
DigmBio and AxcesoBiopharma Partner to Co-develop Next-Generation PARP1 PROTAC-Based Cancer Therapeutics . READ MORE Medigate News Mar 27, 2026
DigmBio to Pursue U.S. Orphan Drug Designation and Accelerated Approval Strategy . READ MORE BIO Insight Feb 27, 2026
Leading the Industry by Developing Next-generation Therapeutics for Cancer and Dementia . READ MORE Hankookilbo Dec 22, 2025
DigmBio Opens Suwon Research Center, Expanding Dual-Hub R&D Across Suwon and Pangyo . READ MORE The Yakup Dec 18, 2025
DigmBio’s Parkinson’s Disease Program Awarded Korea National Drug Development Funding . READ MORE The Yakup Dec 4, 2025
Kim Jeongmin, CEO of DigmBio, presented Digmbio Pipeline at 'BIOLEADERS CLUB' Kim Jeongmin, CEO of DigmBio, said, "The possibility of global technology transfer for our new drug candidate DM5167↑" Kim Jeong-min, CEO of DigmBio, disclosed the development status of the new drug candidate 'DM5167' and future technology transfer strategy at the '25th Bio Leaders Club' hosted by <News 1> on the 24th.https://www.news1.kr/bio/gene . . . READ MORE News 1 June 24, 2025
Kim Jeongmin, CEO of DigmBio, interviewed with the Korea Economic Daily & presented the current pipelines at the Hankyung Bioinsight monthly Interview with CEO Kim Jeong-min June 20, 2025 DM5167, a second-generation PARP inhibitor, is undergoing a phase 1 clinical trial in patients with advanced breast cancer. Partial remission was confirmed at the lowest dose.It is superior to AstraZeneca in efficacy and safety.High brain penetration rate, excellent effect on brain metastasesOptimistic abou . . . READ MORE BIO Insight June 20, 2025
Digmbio, with a $12 billion investment, accelerates clinical trials of its anticancer drug DM5167 Participation in Series A rounds by Partners Invest and Medytox Venture InvestmentFocus on completing phase 1 clinical trial of selective PARP-1 inhibitorNews 1, Reporter Jin-Joong Hwang,   Digmbio, which secured 12 billion won in funding through Series A investment, is starting clinical trials for its next-generation anticancer drug candidate and . . . READ MORE News1 May 30, 2025
Ministry of SMEs and Startups, 50 Baby Unicorns Selected for 2025... Half Are AI A total of 350 applicants were selected up to this year... Various benefits, including up to 300 million won in market development funds.The Ministry of SMEs and Startups announced on the 26th that it has selected 50 ‘baby unicorn’ companies with a high potential to grow into global unicorns.The Baby Unicorn Development Project is part of the "Global Unicorn . . . READ MORE Companies May 26, 2025

검색